-10.3%
ORCL vs MRNA
+153.9%
-164.2%
-68.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.5% | -2.2% | -6.3% | -8.4% |
| 7D | -19.3% | -12.7% | -6.6% | -18.8% |
| 30D | -21.6% | -20.7% | -1.0% | -20.9% |
| 3M | -28.5% | +46.3% | -74.8% | -29.7% |
| 6M | -45.8% | +305.2% | -351.1% | -51.9% |
| YTD | -47.4% | +561.2% | -608.6% | -56.4% |
| 1Y | -51.3% | +772.1% | -823.4% | -61.1% |
| 3Y | -10.3% | +147.0% | -157.3% | -28.8% |
| All | -10.3% | +153.9% | -164.2% | -28.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling